Evidence map›Paper›PMID 38951654›Full record

ArticleScientific reports2024

DUSP1 and SOX2 expression determine squamous cell carcinoma of the salivary gland progression.

Lucía Acero-Riaguas, Ana Belén Griso-Acevedo, Alejandro SanLorenzo-Vaquero, Blanca Ibáñez-Herrera, Sara María Fernandez-Diaz, Marta Mascaraque, Rocío Sánchez-Siles, Iván López-García, Carlos Benítez-Buelga, Elena Ruiz Bravo-Burguillos and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lucía Acero-Riaguas *Laboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Ana Belén Griso-Acevedo *Laboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Alejandro SanLorenzo-VaqueroLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Blanca Ibáñez-HerreraLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Sara María Fernandez-DiazLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Marta MascaraqueLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.ORCID 0000-0002-9677-921X
Rocío Sánchez-SilesLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Iván López-GarcíaLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Carlos Benítez-BuelgaInstituto de Investigaciones Biomédicas CSIC/UAM and CIBER de Enfermedades Raras (CIBERER), 28029, Madrid, Spain.
Elena Ruiz Bravo-BurguillosLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Beatriz CasteloMedical Oncology Department, University Hospital La Paz, 28046, Madrid, Spain.
José Luis Cebrián-CarreteroLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain.
Rosario PeronaInstituto de Salud Carlos III and CIBER de Enfermedades Raras (CIBERER), 28029, Madrid, Spain.
Leandro SastreInstituto de Investigaciones Biomédicas CSIC/UAM and CIBER de Enfermedades Raras (CIBERER), 28029, Madrid, Spain.
Ana Sastre-PeronaLaboratory of Translational Research in Maxillofacial Surgery and Head and Neck Cancer, IdiPAZ, 28046, Madrid, Spain. ana.sastre.perona@idipaz.es.

Funding

Comunidad de Madrid PEJ-2020-AI/BMD-17846Comunidad de Madrid PEJ-2021-TL_BMD-21631Comunidad de Madrid PEJ-2023-AI/SAL-GL-27700Comunidad de Madrid PI_SEPE_ASPFundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) POSTD20042BENFundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) WCRPY224338SASTGilead Sciences (Gilead) GLD22/0166Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CD19/00063Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CD23/00167Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI20/00329Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI20/00335Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI22/01512Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PMP22/00083Worldwide Cancer Research 23-0272
6 · The paper itself

Abstract

Salivary gland squamous cell carcinomas (SG-SCCs) constitute a rare type of head and neck cancer which is linked to poor prognosis. Due to their low frequency, the molecular mechanisms responsible for their aggressiveness are poorly understood. In this work we studied the role of the phosphatase DUSP1, a negative regulator of MAPK activity, in controlling SG-SCC progression. We generated DUSP1 KO clones in A253 human cells. These clones showed a reduced ability to grow in 2D, self-renew in ECM matrices and to form tumors in immunodeficient mice. This was caused by an overactivation of the stress and apoptosis kinase JNK1/2 in DUSP1

Indexed as

Carcinoma, Squamous CellDisease ProgressionDual Specificity Phosphatase 1Salivary Gland NeoplasmsSOXB1 Transcription FactorsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceDual Specificity Phosphatase 1DUSP1 protein, humanSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID38951654
PMCPMC11217270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.